ReviewArchivum immunologiae et therapiae experimentalis
Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.
Review in Archivum immunologiae et therapiae experimentalis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Clinical relevance of the cagA and vacA s1m1 status and antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis.BMC infectious diseases · 2022Pooled it
- Chemoprevention of gastric cancer development afterWorld journal of gastroenterology · 2020Pooled it
- Helicobacter pylori eradication: influence of interleukin-1beta -31 C/T polymorphism.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesTrial
- Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationTrial
- Multiplex fluorescent PCR-based detection of Helicobacter pylori nucleic acid and antibiotic resistance genes in clinical stool samples: a performance evaluation from Gansu Province, China.BMC infectious diseases · 2026Article
- Vonoprazan-Containing Triple Therapy Based on Clarithromycin Susceptibility May Be Definitive Treatment Strategy for Eradication ofJGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Differences and trends in worldwide clinical guidelines forTranslational gastroenterology and hepatology · 2026Review
- A comprehensive study of Helicobacter pylori infection: molecular analysis, antibacterial susceptibility, and histopathological examination.Antonie van Leeuwenhoek · 2023Article
- Study of vacuolating cytotoxin A (vacA) genotypes of ulcerogenic and non-ulcerogenic strains ofSaudi journal of biological sciences · 2023Article
- Relationship between antibiotic resistance and the cagA and vacA genotypes among Helicobacter pylori strain isolates from patients in Xi'an.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Susceptibility patterns and virulence genotypes ofWorld journal of gastroenterology · 2023Article
- Article
- Clarithromycin-resistant H. pylori primary strains and virulence genotypes in the Northeastern region of Brazil.Revista do Instituto de Medicina Tropical de Sao Paulo · 2022Article
- Article
- Influence ofFrontiers in pharmacology · 2021Review
- Effect of Antibiotic Susceptibility andAntibiotics (Basel, Switzerland) · 2020Article
- The Influence ofThe application of clinical genetics · 2020Article
- High Prevalence of Antibiotic Resistance in IranianJournal of clinical medicine · 2019Article
- DifferentialPathogens (Basel, Switzerland) · 2019Article
- Can bacterial virulence factors predict antibiotic resistantWorld journal of gastroenterology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The cure rates of Helicobacter pylori infection by using a combination of a proton pump inhibitor (PPI) and antimicrobial agents are mainly influenced by bacterial susceptibility to antimicrobial agents and the magnitude of acid inhibition during the treatment. Currently used empirical triple therapies do not reliably produce a > or =80% cure rate on an intention-to-treat basis. Therefore, tailored regimens based on relevant microbiological findings and pharmacogenomics are recommended for attaining an acceptable > or =95% cure rate. Recently, virulence factors of H. pylori, such as cagA and vacA, are reported to be major factors determining the cure rates. Individuals infected with strains with cagA-negative and vacA s2 genotypes have significantly increased risk of eradication failure of H. pylori infection. These virulence factors enhance gastric mucosal inflammation and are associated with the development of peptic ulcer and gastric cancer. H. pylori virulence factors induce proinflammatory cytokines, such as interleukin (IL)-1, IL-8, and tumor necrosis factor (TNF)- which influence mucosal inflammation and/or gastric acid secretion. When physicians select an H. pylori eradication regimen with an acceptable cure rate, they might need to consider H. pylori virulence factors, especially cagA and vacA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.